Trial reportJournal of immunology (Baltimore, Md. : 1950)1999
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.
Trial report in Journal of immunology (Baltimore, Md. : 1950), 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 185 citations in OpenAlex.
- gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.The New England journal of medicine · 2011Trial
- Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma.Cancer immunology, immunotherapy : CII · 2005Trial
- Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma.British journal of cancer · 2004Trial
- Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration.Journal of immunotherapy (Hagerstown, Md. : 1997)Trial
- Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer.Pharmaceuticals (Basel, Switzerland) · 2023Review
- IL-17-producing γδT cells ameliorate intestinal acute graft-versus-host disease by recruitment of Gr-1Bone marrow transplantation · 2021Article
- Melanoma vaccines: mixed past, promising future.The Surgical clinics of North America · 2014Review
- HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer.Investigational new drugs · 2014Article
- Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy.World journal of urology · 2014Review
- T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.Cancer immunology, immunotherapy : CII · 2012Article
- Therapeutic cancer vaccines: are we there yet?Immunological reviews · 2011Review
- GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.Breast cancer research and treatment · 2010Article
- Clinical applications of a peptide-based vaccine for glioblastoma.Neurosurgery clinics of North America · 2010Review
- Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.Clinical immunology (Orlando, Fla.) · 2009Article
- Functions of γC cytokines in immune homeostasis: current and potential clinical applications.Clinical immunology (Orlando, Fla.) · 2009Review
- Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.American journal of immunology · 2009Article
- Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines.Annals of surgical oncology · 2008Article
- Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides.Clinical immunology (Orlando, Fla.) · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 2 countries.
Funding
Abstract
Patients with metastatic melanoma were immunized with an immunodominant peptide derived from the gp100 melanoma-melanocyte differentiation Ag that was modified to increase binding to HLA-A+0201. A total of 10 of 11 patients who received the g209-2M peptide alone developed precursors reactive with the native g209 peptide, compared with only 5 of 16 patients who received g209-2M peptide plus IL-2 (p2 = 0.005). Peptide reactivity closely correlated with the recognition of HLA-A+0201 melanoma cells (p < 0. 001). The decrease in immune reactivity when peptide was administered with IL-2 appeared specific for the immunizing peptide, since reactivity to an influenza peptide resulting from prior exposure was not affected. Preexisting antitumor precursors did not decrease when peptide plus IL-2 was administered. The administration of GM-CSF or IL-12 also resulted in a decrease in circulating precursors compared with the administration of peptide alone, though not as great a decrease as that seen with IL-2. Immunization with peptide plus IL-2 did, however, appear to have clinical impact since 6 of the 16 patients (38%) that received peptide plus IL-2 had objective cancer regressions. It thus appeared possible that immunization with peptide plus IL-2 resulted in sequestering or apoptotic destruction of newly activated immune cells at the tumor site. These represent the first detailed studies of the impact of immunization with tumor peptides in conjunction with a variety of cytokines in patients with metastatic cancer.
Indexed as
Identifiers
10415076PMC2249693W1936376546What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.